Side-by-side · Research reference

AHK-CuvsEpitalon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BHuman-MechanisticAUTO-DRAFTED8/37 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

01Mechanism of Action

Parameter

AHK-Cu

Epitalon

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Feedback intact?

—

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Antibody development

—

02Dosage Protocols

Parameter

AHK-Cu

Epitalon

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

Once daily during a cycle

Route

Topical — scalp or dermal application

—

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Duration

Not established — cosmetic protocols typically 8–12 weeks

10–20 day cycles, 1–2× per year

Standard dose

—

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

Lower / starter dose

—

2.5 mg / day

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep preferred (pineal alignment)

Half-life

—

Hours (estimated)

04Side Effects & Safety

Parameter

AHK-Cu

Epitalon

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Injection site reaction

—

Mild irritation

Sleep architecture

—

Improved subjective sleep quality (anecdotal)

Cancer risk

—

Theoretical via telomerase activation in pre-malignant cells

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid

Antibody formation

—

Not reported

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

Epitalon

·Family history of cancer

05Administration Protocol

Parameter

AHK-Cu

Epitalon

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

SQ — abdomen preferred. Rotate sites.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

Pre-sleep preferred to align with pineal axis.

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

Epitalon

— no documented stacks